| Sub group | Success rate [no. of successes/total no. (%)] for: | ||||||||||||||||
| Vancomycin group | FDC group | ||||||||||||||||
| Empirical therapy | Shifted therapy (FDC) | Colistin add on therapy | Empirical therapy | Shifted therapy | Colistin add on therapy | ||||||||||||
| Evaluable patients for efficacy analysis | 59 | 54 | |||||||||||||||
| Patients with infections caused vancomycin and FDC susceptible MRSA (vancomycin MIC ≤ 1) | |||||||||||||||||
| Overall clinical success | 31/37 (83.78) | 31/33 (93.93) | |||||||||||||||
| Treatment regime-wise | 24/37 (64.86) | 7/8 (87.5) | 0 (0) | 28/33 (84.84) | 0 (0) | 3/5 (60) | |||||||||||
| Age | |||||||||||||||||
| ≤50 years | 07/11 (63.63) | 2/2 (100) | 0 (0) | 6/7 (85.71) | 0 (0) | 1/1 (100) | |||||||||||
| ≥51 years ≤75 years | 14/19 (73.68) | 4/4 (100) | 0 (0) | 15/19 (78.94) | 0 (0) | 2/4 (50) | |||||||||||
| ≥76 years | 03/07 (42.85) | 1/2 (50) | 0 (0) | 07/07 (100) | 0 (0) | 0 (0) | |||||||||||
| APACHE II score | |||||||||||||||||
| <15 | 19/27 (70.37) | 5/6 (83.33) | 0 (0) | 22/25 (88) | 0 (0) | 2/3 (66.66) | |||||||||||
| ≥15 | 5/10 (50) | 2/2 (100) | 0 (0) | 6/8 (75) | 0 (0) | 1/2 (50) | |||||||||||
| Types of pneumonia | |||||||||||||||||
| Community associated | 04/05 (80) | 1/1 (100) | 0 (0) | 4/4 (100) | 0 (0) | 0 (0) | |||||||||||
| Health-care associated | 13/17 (76.47) | 4/4 (100) | 0 (0) | 17/21 (80.95) | 0 (0) | 3/4 (75) | |||||||||||
| Hospital associated | 9/12 (75) | 3/3 (100) | 0 (0) | 5/7 (71.42) | 0 (0) | 1/2(50) | |||||||||||
| Ventilator associated | 12/18 (66.66) | 5 /6 (83.33) | 0 (0) | 14/17 (82.35) | 0 (0) | 2/3 (66.66) | |||||||||||
| Causative pathogen | |||||||||||||||||
| MRSA only | 22/26 (92.30) | 3/3 (100) | 0 (0) | 25/27 (92.59) | 0 (0) | 1/2 (50) | |||||||||||
| MRSA mixed with other pathogens | 2/11 (18.18) | 4/5 (80) | 0 (0) | 3/6 (50) | 0 (0) | 2/3 (66.66) | |||||||||||
| Type of co-morbidities | |||||||||||||||||
| Diabetes mellitus | 8/11 (72.72) | 3/3 (100) | 0 (0) | 08/10 (80) | 0 (0) | 2/2 (100) | |||||||||||
| Cardiac diseases | 12/16 (75) | 4/4 (100) | 0 (0) | 11/14 (78.57) | 0 (0) | 2/3 (66.66) | |||||||||||
| Kidney diseases | 2/3 (66.66) | 1/1 (100) | 0 (0) | 1/1 (100) | 0 (0) | 0 (0) | |||||||||||
| Chronic obstructive pulmonary disease (COPD) | 16/21 (76.19) | 4/5 (80) | 0 (0) | 18/21 (85.71) | 0 (0) | 2/3 (66.66) | |||||||||||
| Neurological disorders | 3/4 (75) | 1/1 (100) | 0 (0) | 4/4 (100) | 0 (0) | 0 (0) | |||||||||||
|
| 0/1 (0) | 1/1 (100) | 0 (0) | 2/3 (66.66) | 0 (0) | 1/1 (100) | |||||||||||
| Patients with infections caused vancomycin resistant and FDC susceptible MRSA (vancomycin MIC ≥ 1) | |||||||||||||||||
| Overall clinical success | 21/22 (95.45) | 19/21 (90.47) | |||||||||||||||
| Treatment regime-wise | 0/22 (0) | 18/22 (81.81) | 3/4 (75) | 16/21 (76.19) | 0 (0) | 3/5 (60) | |||||||||||
| Age | |||||||||||||||||
| ≤50 years | 0/10 (0) | 9/10 (90) | 1/1 (100) | 6/9 (66.66) | 0 (0) | 1/3 (33.33) | |||||||||||
| ≥51 years ≤75 years | 0/8 (0) | 7/8 (87.5) | 1/1 (100) | 7/9 (77.77) | 0 (0) | 1/2 (50) | |||||||||||
| ≥76 years | 0/4 (0) | 2/4 (50) | 1/2 (50) | 3/3 (100) | 0 (0) | 0 (0) | |||||||||||